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Background. We conducted a 3 arm cluster randomized trial of three MRSA pre-
vention strategies in 74 ICUs at 43 hospitals which demonstrated universal decoloni-
zation with chlorhexidine and mupirocin in adult ICUs resulted in a 44% reduction in
risk of bloodstream infection due to all pathogens.(N Engl J Med 2013; 368:2255-2268)
Implementing novel evidence based strategies across a large healthcare system presents
challenges to scale to reach high compliance.
Methods. Starting in March 2013 HCA implemented universal decolonization in
over 350 adult ICUs in over 160 acute care hospitals. Planning and deployment tactics
occurred thru central coordination with corporate infection prevention using intranet
available toolkit resources, operational and process measures from a common EHR
system and coaching calls. Key stakeholders included leadership champions, healthcare
providers, infection preventionists, pharmacists, IT&S and supply chain. Primary anal-
ysis was reduction in HAI CLABSI using National Healthcare Safety Network (NHSN)
surveillance deﬁnitions excluding the 74 ICU hospitals in the original trial. We deﬁned
the pre-implementation period as beginning in January, 2011 and ending in December
2012, and the post-implementation period as beginning in July 2013 and ending in
February 2014. The period of phase-in, between January and June 2013, was omitted
from analysis.
We ﬁt a Poisson Generalized Linear Mixed Model regression for the number of in-
fections to assess differences between the pre- and post-implementation periods while
accounting for hospital and unit level correlation. We assessed the possibility of trend
over time, and adjusted for seasonal effect, and number of beds in the unit. The log
total number of central lines was the offset.
Results. There was no evidence of trend over time in either the pre or post imple-
mentation period. After implementation, the estimated rate of CLABSI decreased by
31% (p < .0001, 95% conﬁdence interval [16%,40%]). Adjusting for seasonality and
number of beds minimally affected these results.
Conclusion. Universal decolonization of ICU patients was associated with signiﬁ-
cant decline in CLABSI across a large community hospital system conﬁrming our orig-
inal trial. Rapid implementation is reproducible in a learning healthcare system.
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